Psychiatric Drug Effects
Home > References


Adams W., Kusljic S., Van den Buuse M. “Serotonin depletion in the dorsal and ventral hippocampus: Effects on locomotor hyperactivity, prepulse inhibition and learning and memory”  Neuropharmacology Volume 55, Issue 6, November 2008, Pages 1048-1055

Alexander B., Lund BC. Tardive Dyskinesia  Clinical Psychopharmacology Seminar 1996-1997 Virtual Hospital

Aleem M, Choudhari J, Padwal V, Balasinor N, Parte P, Gill-Sharma MK. Hyperprolactinemia affects spermiogenesis in adult male rats. Journal of Endocrinological Investigation 2005 (28); 1,39-48

Annals of Internal Medicine  How Common Are High Cortisol Levels in Apparently Healthy People with Osteoporosis? 16 October 2007 | Volume 147 Issue 8 | Page I-48

Barnes, T.R.E. and Bridges, P.K. (1980) 'Disturbed behaviour induced with high dose antipsychotic drugs', British Medical Journal 281:274-5

Baumgartner A., (2000) ‘Thyroxine and the treatment of affective disorders: an overview of the results of basic and clinical research’ The International Journal of Neuropsychopharmacology, 3: 149-165 Cambridge University Press

Benzer, T., 2002) ‘Neuroleptic Malignant Syndrome’, Medicine Journal. Vol 3: 1

Benno Muller-Hill (1988) Murderous Science: Elimination by Scientific Selection of Jews, Gypsies, and Others. Germany 1933-1945

Beumont, P. “Psycho-Neuro-Endocrine Mechanisms” Australian Journal of Forensic Sciences Volume 13, Issue 2 December 1980 Page 40 - 47


Blass, D.M., Chuen, M.  Olanzapine-Associated Hypothermia” Psychosomatics 45:135-139, April 2004

Blueprints in Psychiatry (1998) Blackwell Science, Inc., Malden, Massachusetts

Bowers, M.B.Jr., Swigar, M.E., (1988) ‘Psychotic patients who become worse on neuroleptics’. J Clin Psychopharmacol Dec;8(6):417-21 Yale University School of Medicine, Dept of Psychiatry, New Haven, Connecticut.

Braude W, M., Barnes, T.R.E. and Gore S.M. (1983) 'Clinical characteristics of akathesia: a systematic investigation of acute psychiatric inpatient admissions', British Psychiatric journal of Psychiatry 143: 139-50.

Bray J., Clarke C., Brennan G., Muncy T. (2008) Should we be ‘pushing meds’? The implications of pharmacogenomics Journal of Psychiatric and Mental Health Nursing Vol 15 Number 5 357-364    

Braylet M. C., Yon V., Loas G., Noisette C., Cause of mortality in schizophrenic patients: prospective study of years of a cohort of 150 chronic schizophrenic patients Encephale 26 (2000):32-41
Breggin, P., (1997) ‘Brain disabling treatments in psychiatry’. 2-11.

Breggin R. B. (2006) Intoxication Ansognosia: The Spell Binding Effect of Psychiatric Drugs Ethical Human Psychology and Psychiatry. Vol 8, Number 3 Fall/Winter 2006

Casey DE (1997) The relationship of pharmacology to side effects. Journal of Clinical Psychiatry 58, Suppl 10,55-62

Chouinard, G. and Jones, B.D. (1980) ‘Neuroleptic-induced super sensitivity psychosis: clinical and pharmacological characteristics’, American Journal of Psychiatry 137: 16-21.

Circare (2000) Evidence of Neuroleptic –Induced Brain Damage in Patients: A partial, annotated Bibliography (1998) MRI studies that demonstrates structural brain changes in schizophrenic patients treated with both standard and ‘typical’ neuroleptic medication. P. 10 American Journal of Psychiatry. 1996

Compton M. T., Risperidone-Induced Ejaculatory Disturbances” Psychiatr Serv, March 1, 2002; 53(3): 347 - 347.

Craft, T., Nolan, J.P., Parr, M.J.A., (2004) Key Topics in Clinical Care 2nd Edition

Crane, G.E (1968) 'Tardive Dyskinesia in patients treated with neuroleptics: a review of the literature', American Journal of Psychiatry (supplement) 124: 40-8

Crow, T.J., MacMillan, J.F., Johnson, A.L., and Johnstone, E.C., (1986) 'The Northwick Park study of first episodes of Schizophrenia: 11. A randomised controlled trial of prophylactic medication', British Journal of Psychiatry. 148; 120-7.

Curson, D., Patel, M., Liddle, P.F. and Barnes, T.R. (1988) Psychiatric Morbidity of a long-stay hospital population with chronic schizophrenia, and implications for future community care', British Medical Journal 279: 818- 22.

Davies, J., Schaffer, C. B., Killan, G.A., et al. (1980) ‘Important issues in the drug treatment of schizophrenia’, Schizophrenia Bulletin 6:70-87.

De Alarcon, R. and Carney, M.W.P. (1969) 'Severe depressive mood changes following slow release intramuscular fluphenazine injection', British Medical Journal iii: 546-7.

Dome P., Teleki Z., Kotanyi R. (2006) “Paralytic ileus associated with combined atypical antipsychotic therapy” Progress in Neuro-Psychopharmacology and Biological Psychiatry, Volume 31, Issue 2, 30 March 2007, Pages 557-560

Douglas I.J., Smeeth L., (2008) Exposure to antipsychotics and risk of stroke: self controlled case series study BMJ 2008; 337: a1227

Drake, R.E. and Ehrlich, J. (1985) 'Suicide attempts associated with akathesia', American Journal of Psychiatry.

Duke University. (2002)

Edwards, H. (1970) ‘The significance of brain damage in persistent oral dyskinesia’. British Journal of Psychiatry, 116. 271-275.

Electric Medicines Compendium Novartis Pharmaceuticals UK Ltd 2003

Erasmus, U. (1986,1993) "Fats that Heal Fats that Kill", Alive Books, Fraser Park Drive, Burnaby BC Canada V5J 5B9. P 37

Elman I., Goldstein D. S., Eisenhofer G., Folio J., Malhotra A. K., Adler C.M., Pickar D., Breier A. Mechanism of Peripheral Noradrenergic Stimulation by Clozapine. Neuropsychopharmacology (1999) 20 29-34.10.1038/sj.npp.1395230

Emerson GM., Gray NM., Jelinek GA: Organophosphate poisoning in Perth, Australia 1987-1996. J Emerg Med 1999 Mar-Apr; 17(2)

Furtado M. C., Chan L., (2003) Toxicity, Organophosphate - 93k

Foltz R. M. (2000) ‘Understanding the Medicated Patient: A Phenomenological Study of Antipsychotic Medications In Schizophrenia’. Illinois school of Professional Psychology Faculty 

Garfield, D. (1995). ‘ Unbearable effect: A guide to the psychotherapy of psychosis’. New York: John Wiley & Sons, Inc.

General Medical Council (1996) Good medical practice; guidance from the general Medical Council. London: GMC

Gillin, J. Christian et al. The Psychedelic Model of Schizophrenia: The Case of N,N-Dimethyltryptamine. American Journal of Psyciatry 133(2):203-8 (Feb,1976).

Grob, G., (1994). ‘The mad among us: A history of the care of America’s mentally ill’. Cambridge: Harvard University Press. p.27

R. E. Gur et al, “A follow up Magnetic Resonance Imaging study of Schizophrenia; Relationship of Neuroanatomical Changes to Clinical neurobehavioral Measures” Archives of General Psychiatry  55:2 (1998):145-152.

Gurrera, R. J., '(1999) Sympathoadromal Hyperactivity and the Etiology of Neuroleptic Malignant Syndrome' Am J Psychiatry 156: 169-180, February

Haddad PM, Wieck A. (2004) Antipsychotic-induced: mechanisms, clinical features and management. PUB MED 64(20):2291-314.

Heiskanen, T., Niskanen, L., Lyytikainen, R., et al (2003) Metabolic syndrome in patients with schizophrenia. Journal of Clinical Psychiatry, 64, 575 -579.

Herrera, J.N., Sramek, J.J., Costa, J,F, et al. (1998) 'High potency neuroleptics and violence in schizophrenia', Journal of Nervous and Mental Diseases 176: 558-61.

Hibbard K.R., Propst A., Frank D.E., Wyse J. “Fatalities Associated With Clozapine-Related Constipation and Bowel Obstruction: A Literature Review and Two Case Reports” Psychosomatics 2009; 50:416-419


Hiroi T., Imaoka S., Funae Y. Dopamine Formation from Tyramine by CYP2D6 Department of Chemical Biology, Osaka City University Medical School, 1-4-3, Asahimachi, Abeno-ku, Osaka, 545-8585, Japan Received 20 July 1998.  Available online 12 April 2002.

Hong, Chen-Jee a,b; Lin, Ching-Hua c; Yu, Younger W. -Y. c; Yang, Kuan-Hung c; Tsai, Shih-Jen a,b (2001) Genetic variants of the serotonin system and weight change during clozapine treatment. Pharmacogenetics. 11(3):265-268, April 2001.

Howard LM, Kirkwood G, Leese M. Risk of hip fracture in patients with a history of schizophrenia. British Journal of Psychiatry. 2007:190,129-134.

Hummer M., Malik P., Gasser R W,. Hofer A., Kemmler G,. Naveda R C M., Rettenbacher M A., Fleischhacker WW. (2005) Osteoporosis in Patients with Schizophrenia Am J Psychiatry 162:162-167, January 2005

Imperato A., Obinu MC., Casu MA., Mascia MS., Dazzi L., Gessa GL. (1993) Evidence that neuroleptics increase striatal acetylcholine release through stimulation of dopamine D1 receptors. The Journal of Pharmacology and Experimental Therapeutics Volume 266, Issue 2, pp. 557-562, 08/01/1993

Irwin M. Treatment of Schizophrenia Without Neuroleptics: Psychosocial Interventions Versus Neuroleptic Treatment  Ethical Psychology and Psychiatry Vol. 6 Number 2 Summer 2004 

Jackman HL., Meltzer HY. (1983) Kinetic constants of platlet monoamine oxidase in schizophrenia. Am J Psychiatry 1983; 140;1044-1047           

Grace E. Jackson, MD. (2009), "Drug-Induced Dementia: a Perfect Crime" AuthorHouse

Jackson, G.E., (2005) “Rethinking Psychiatric Drugs: A Guide for Informed Consent" Authorhouse US LINK

Johnson, D.A.W. (1979) ’Further observations on the neuroleptic maintenance therapy in schizophrenia’, British Journal of Psychiatry. 135; 525-30.

Johnson, P.B., Ramirez, P.M., Opler, L.A. and Malgady, R. (1994) 'Relationship between neuroleptic dose and positive and negative symptoms', Psychological Reports 74: 481-2.

Kahne, G.L. (1989) ‘Rebound Psychoses following the discontinuation of a high potency neuroleptic’ Can J Psychiatry Apr; 34 (3): 227-229

Karon, N., (1992) ‘The fear of Understanding Schizophrenia’ The General Psychologist. 32 (1). 3-14

Kearney T., Johnston D.G.   Growth hormone deficiency in adults. The Pharmaceutical Journal Vol 264 No 7102 p953-955 June 24, 2000 Continuing education

Kirkpatrick, B., Alphs, L., Buchanan, R., W. (1992) ‘Behavioural Toxicity of antipsychotic drugs’. J Clin Psychiatry (1987) Sept; 48 Suppl:13-9.

Kirkpatrick B. Messias E.,. Harvey P.D., Fernandez-Egea E., Bowie C.R. “Is Schizophrenia a Syndrome of Accelerated Aging?” Schizophrenia Bulletin 2008 34(6): 1024-1032  

Klawans, H.L. (1973) 'The pharmacology of tardive dyskinesia', American Journal of Psychiatry 130: 82-6.

Krausz M.,  Moritz SH., Naber D., Lambert M., Andresen B., (1999)
Neuroleptic-induced extrapyramidal symptoms are accompanied by cognitive dysfunction in schizophrenia European Psychiatry Vol: 14 Issue 2 April 1999 pp 82-88

Kristin S P., Rosenfeld J. A., (2001) Evaluation and Treatment of Galactorrhea American Family Physicians  Franklin Square Hospital, Baltimore, Maryland

Kuehn B M. Antipsychotic Risks JAMA 2009;301(8):817.

Kutsky, R. J., (1973) ‘Handbook of Vitamins, Minerals and Hormones 2nd Edition’, Van Nostrand Reinhold Company New York, p 369

Lader, M. (1994) ‘Neuroleptic-induced  Deficit Syndrome’, Acta. Psychiatr. Scand. Suppl. 380:6-7

Layton D, Cox A. Antipsychotics and stroke: the story to date. The Pharmaceutical Journal 2009; 282: 30

Lelliott. P. Paton C. Harrington M. Konsolski M. Sensky T. Okocha C. (2002) The influence of patient variables of polypharmacy and combined high dose of antipsychotic drugs for inpatients.  Psychiatric Bulletin (2002), 26, 411^414

Lewander, T. (1994) 'Neuroleptics and the neuroleptic induced deficit syndrome', Acta Psychiatrica Scandinavica 89 supplement 380: 8-13.

Lieberman J.A (2004) Metabolic Changes Associated With Antipsychotic Use. Primary Care Companion Journal of Clinical Psychiatry 6 (Suppl.2), 8-13.

Lieberman J. A. (2004) Managing Anticholinergic Side Effects

Prim. Care Companion J Clin Psychiatry 2004:6 [Suppl 2: 20-23]

Lieberman M., Marks A.D., Smith C,. (2006) Marks' Essential Medical Biochemistry. p497 Lippinet Williams &Wilkins

Madsen Al, Keiding N, Karle A, Esbjerg S, Hemmingsen R: (1998) “Neuroleptics in progressive structural brain abnormalities in psychiatric illness.” The Lancet, 352 (9130) 784

Manendra Bishnoi, Anil Kumar, Kanwaljit Chupra & Shrinivas Tulkarni

“Comparative neurochemical changes associated with chronic administrations of typical and atypical neuroleptics: implications tardive dyskinesia.” Indian Journal of Experimental Biology Vol.45 Feb. 2007, pp175-179

Marder S.R. (2005) Subjective experiences on antipsychotic medications: synthesis and conclusions Acta Psychiatrica Scandinavica 111 (s427) , 43–46

Markowe, M., Steinert, J. and Heyworth-Davies, F. (1967) 'Insulin and chlorpromazine in schizophrenia: a ten year comparative study', British Medical Journal 113: 1101-6.

Martensson, L., (1998) Deprived of Our Humanity The Case against Neuroleptic Drugs Printed in European Community (Germany)

Meaney AM., Smith S., O’brien M.,  Murray M., O’keane V. Effects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia The British Journal of Psychiatry (2004) 184: 503-508 © 2004

Mehtonen, O.P., Aranko, K., Malkonen, L. et al. (1991) 'A study of sudden death associated with the use of anti psychotic or antidepressant drugs', Acta Psychiatrica Scandinavica 84: 58-64.

Miller, R. and Chouinard, G. (1993) ‘Loss of striatal cholinergic neurons as a basis for tardive dyskinesias, neuroleptic-induced supersensitivity psychosis and refractory schizophrenia’. Biological Psychiatry. Vol 34 (10), Nov 1993, 713-718.

Meltzer HY., Duncavage MB., Jackman H., Arora RC., Tricou BJ., Young B. (1982) Effect of neuroleptic drugs on platelet monoamine oxidase in psychiatric patients. Am J Psychiatry 1982; 139:1242-1248

Meszaros Z., Borcsizky D., Mate M., Tarcali J., Tekes K., Magyar K. (1998) MAO inhibitory side effects of neuroleptics and platlet serotonin content in schizophrenic patients. J Neural Transm Suppl. 1998;52;79-85


Moncrieff J. (2006) Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse. Acta Psychiatr Scand: 114: 3-13

Moncrieff J (2006) Why is it so difficult to stop psychiatric drug treatment? It may have nothing to do with the original problem. Medical Hypothesis 67: 517-23

Northern Ireland Association for Mental Health

Moran M. Schizophrenia Drugs Differ Considerably In Metabolic-Syndrome Risk Psychiatr News April 21, 2006 Volume 41, Number 8, page 39 © 2006

Mortimer A M. (2007) Relationship between estrogen and schizophrenia. Expert Review of Neurotherapeutics 7:1, 45

Mukherjee, S., Rosen, A.M., Cardenas, C., Varia, V. and Orlarte, S. (1982) 'Tardive Dyskinesia in psychiatric outpatients: a study of prevalence and association with demographic clinical and drug history variables', Archives of General Psychiatry 39:466-9.

Muller-Hill, B., (1988) ‘Murderous Science: Elimination by Scientific Selection of Jews, Gypsies, and others in Germany’. 1993-1994. New York: Oxford University Press.    

National Institute for Clinical Excellence (2002) Guidance on the Use of Newer (Atypical) Antipsychotic Drugs for the Treatment of Schizophrenia. (Technology Appraissal Guidance, No.43). London: National Institute for Clinical Excellence.

Nelson E (2001) Akathisia - A Brief Review Scottish Medical Journal

O'Keane, V. “Antipsychotic-induced hyperprolactinaemia, hypogonadism and osteoporosis in the treatment of schizophrenia” Journal of Psychopharmacology, Vol. 22, No. 2 suppl, 70-75 (2008)

Ozcanli T, Erdogan A,  Ozdemir S, Onen B, Ozmen M, Doksat K, Sonsuz A. “Severe liver enzyme elevations after three years of olanzapine treatment: A case report and review of olanzapine associated hepatotoxicity” Progress in Neuro-Psychopharmacology and Biological Psychiatry, Volume 30, Issue 6, 30 August 2006, Pages 1163-1166

References and further reading may be available for this article. To view references and further reading you must purchase this article.


Paik, I.H. et al. Platelet MAO in schizophrenics: relationship to sympatomatology and neuropleptics. Biological Psychiatry 23: 93-5 (1988).

Pelizza L, De Luca P, La Pesa M, Borella D (2007) Clozapine-induced intestinal occlusion: a serious side effect. Acta Biomed. 2007 Aug;78(2):144-8

Poa N.R., Edgar P.F., (2007) 'Insulin Resistance Is Associated With Hypercortisolemia in Polynesian Patients Treated With Antipsychotic Medication  Diabetes Care 30:1425-1429.  American Diabetes Association

Popovic V, Doknic M, Maric N, Pekic S, Damjanovic A, Miljic D, Popovic S, Miljic N, Djurovic M, Jasovic-Gasic M, Dieguez C, Casanueva FF.
Changes in neuroendocrine and metabolic hormones induced by atypical antipsychotics in normal-weight patients with schizophrenia. Neuroendocrinology. 2007;85(4):249-56. Epub 2007 Jun 15

Poyurovsky M., Weizman A., (2001) Serotonin-based pharmacotherapy for acute neuroleptic-induced akathisia: a new approach to an old problem The British Journal of Psychiatry (2001) 179: 4-8

Preda and Bowers. Antidepressant-Associated Mania and Psychosis Resulting in Psychiatric Admissions . Journal of Clinical Psychiatry 2001: 62: 30-33).

Purificación Rey-Sánchez, Jesús M Lavado-García, María L Canal-Macías, María A Gómez-Zubeldia, Raúl Roncero-Martín, Juan D Pedrera-Zamorano
Ultrasound bone mass in schizophrenic patients on antipsychotic therapy.  Hum Psychopharmacol 2009 Jan 24(1):49-54

Rinieris F., Christodoulou G.N., Souvatzoglou A., Koutras D.A., Stefanis C. Free-Thyroxine Index in Schizophrenic Patients before and after Neuroleptic Treatment Departments of Psychiatry and Clinical Therapeutics, Athens University Medical School, Eginition Hospital and Alexandra Hospital, Athens Neuropsychobiology 1980;6:29-33 (DOI: 10.1159/000117729)

Robinson D.S., Insulin Secretion and Psychotropic Drugs. Primary Psychiatry. 2006;13(12):26-27

Rogers A., Pilgrim D., Lacey R., (1993) 'Experiencing Psychiatry: Users views of services' London: MIND /Macmillan   

Saha S., Chant D., McGrath J. A Systematic Review of Mortality in Schizophrenia. Is the Differential Mortality Gap Worsening Over Time? Arch Gen Psychiatry. 2007;64:1123-1131.

Samaha A., Seeman P., Stewart J., Rajabi H., Kapur S. (2007) " "Breakthrough" Dopamine Spersensitivity during Ongoing Antipsychotic Treatment leads to Treatment Failure over Time The Journal of Neuroscience, March 14, 2007, 279110:2979-2986:doi:10.1523/JNEUROSCI,5416-06.2007 

Shibasaki M., Crandal C. G., Effect of local acetylcholinesterase inhibition on sweat rate in humans J Appl Physiol 90: 757-762, 2001;  Vol. 90, Issue 3, 757-762, March 2001

Schillevoort I., Boer de A., Weide van der J., Steijns L.S.W., Roos R.A.C., Jansen P. A J., Leufkens H., G., M. (2002). Antipsychotic-induced extrapyramidal syndromes and cytochrome P450 2D6 genotype: a case-control study. Pharmacogenetics. 2002 Apr ;12 (3):235-40 11927839 

Schooler, N.R. (1994) 'Deficit symptoms in schizophrenia: negative symptoms versus neuroleptic-induced deficits', Acta Pyschiatrica Scandinavica (supplement) 380: 21-6.

Silvestre, J.S., Prous, J. Research on adverse drug events. I. Muscarinic M3 receptor binding affinity could predict the risk of antipsychotics to induce type 2 diabetes. Methods Find Exp Clin Pharmacol 2005, 27(5): 289

Simpson, G.M., Davies, J., Jefferson, J.W. et al (1997) 'Sudden deaths in psychiatric patients: the role of neuroleptic drugs' in American Psychiatric Association task force report.

Singh, M.M. (1976) 'Dysphoric response to neuroleptic treatment in schizophrenia and its prognostic significance', Disease of the Nervous Sys 37: 191-5.

Smith, R.C., Strizich, R. and Klass, D. (1978) 'Drug history and tardive dyskinesia', American Journal of Psychiatry 135: 1402-3.

Straus  S. M. J. M., Bleumink G. S., Dieleman J. P., Johan van der Lei, Geert W., 't Jong, Herre Kingma, Miriam C. J. M. Sturkenboom, Bruno H.C. Stricker " Antipsychotics and the Sudden risk of Cardiac Death " archives of Internal Medicine 164 (2004): 1293-1297

Struve F.A., Willner A.E., Cognitive dysfunction and tardive dyskinesia. The British Journal of Psychiatry 143: 597-600 (1983)

Sunderland M., (2005) 'The Science of Parenting' DK Books

Szarfman A, Tonning J M , Levine,  J G, Murali Doraiswamy P.

Atypical Antipsychotics and Pituitary Tumors: A Pharmacovigilance Study Print ISSN: 0277-0008 Volume: 26 | Issue: 6 Cover date: June 2006 Page(s): 748-758


Thomas, P. (1997) ‘The Dialectics of Schizophrenia’. Free Association Books. London / New York.

Thomas, P. and McGuire, R. (1986) 'Orofacial Dyskinesia, Cognitive Function and Medication', British Journal of Psychiatry 149:216-20.

Thompson, C. (1994) 'The use of high dose anti psychotic medication', British Journal of Psychiatry 164: 448-58.

Tranter, T. and Healy, D. (1998) ‘Neuroleptic discontinuation syndromes’. J. Psychopharmacology, 12 (3), 306-311.

Usher K, Foster K & Park T (2006) The metabolic syndrome and schizophrenia: the latest evidence and nursing guidelines for management. Journal of Psychiatric and Mental Health Nursing. 13, 730-734.

Van Putten, T. (1974) ‘Why do schizophrenics patients refuse to take their drugs?’, Archives of General Psychiatry 31 : 239-55

Visi SE,. Ronai A.,Harsing LJr.,Knoll J.(1977) Inhibitory effect of dopamine on acetylcholine release from caudate nucleus.  Pol J Pharmacol Pharm 1977 May-June;29(3):201-11

Waddington J et al, Mortality in schizophrenia: Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study, Br J Psych, 1998, 173; 325-329.

JL Waddington. Cognitive dysfunction, negative symptoms, and tardive dyskinesia in schizophrenia. Archives of General Psychiatry, 44, 907-912, 1987.

Waddington J.l., Youssef H,A., Kinsella A. Mortality in Schizophrenia: "Antipsychotic polypharmacy and abscence of adjunctive anticholinergic drugs over the course of a 10-year prospective study" British Journal of Psychiatry 173 (1998):325-329 

Wade, J.B., Hart, R., Linden, D., Novak, T., Hamar, R. (1989)  ‘Cognitive changes associated with tardive dyskinesia’. Neuropsychiatry, neuropsychology, and Behavioural Neurology, 1(3), 217-227

Wayne, A. R., Chung C.P., Murray K, T., Hall K,. Stein C. M. (2009) Atypical Antipsychotic Drugs and the Risk of Sudden Cardiac Death New England Journal of Medicine  Volume 360:225-235 Number 3

Whitaker, R. (2002), Mad in America, Perseus Publishing. p281.

Wieck, A. Haddad, P. “Hyperprolactinaemia caused by antipsychotic drugs This common side effect needs more attention” BMJ. 2002 February 2; 324(7332): 250–252.

Windgassen K, Wesselmann U, Schulze Mönking H. Galactorrhea and hyperprolactinemia in schizophrenic patients on neuroleptics: frequency and etiology. Neuropsychobiology 1996;33:142-6.

Windgassen, K. (1991) Schizophreniebehandlung aus der sicht des pateinten. Untersuchungen des behandlungsverlaufes und der neuroleptischen therapie unter pathischem aspekt. Berlin: Springer-Verlag.

Wik G., (1995) Effects of neuroleptic treatment on cortisol and 3-methoxy-4-hydroxyphenylethyl glycol levels in blood Journal of Endocrinology, Vol 144, Issue 3, 425-429

Witte P.U. Sander R. Metschler E. 2002 Pharmacogenomics - An exciting tool in drug development and clinical trials. The Imformer newletter from IMfORM

Wolfe.S.M. Sasich. L.D., Pharm.D. Hope. RE. Public Citizen’s Health Research Group. (1999) Worst Pills: Best pills. Pocket Books. New York.

J . Wolstein , R . Grohmann , E . Rüther , H . Hippius (2000) Antipsychotic drugs and venous thromboembolism 
The Lancet , Volume 356 , Issue 9225 , Pages 252 - 252